

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	Colchicine
Brand Name	Myinfla™
Dosage Form(s)	0.5 mg extended-release tablet
Manufacturer	Pendopharm Division of Pharmascience Inc.
Submission Type	New Indication
Use Reviewed	Myinfla is indicated as an add-on therapy to standard of care for the reduction of atherothrombotic events in patients who had a myocardial infarction.
Common Drug	Yes, the CDR recommended: Do Not Reimburse .
Review (CDR)	Visit the CDR website for more details: www.cadth.ca/node/88649 .
Provincial	Myinfla was reviewed internally and was not reviewed by the Drug Benefit Council (DBC) because
Review	the CDR recommended not to list for the reduction of atherothrombotic events in adults with
	coronary artery disease.
Drug Coverage	Non-Benefit
Decision	
Date	July 19, 2022
Reasons	Drug coverage decision is consistent with the CDEC recommendation
	Adding Myinfla to standard preventative treatments lowered patients' chances of having
	major cardiovascular events compared to placebo. However, there were no head-to-head
	studies comparing colchicine with other drugs for the same indication.
	There was not enough evidence to show that Myinfla reduced mortality, heart attack and
	stroke, or improved health-related quality of life.
	The collection and reporting of harms data were incomplete and evidence comparing the
	safety of Myinfla to other drugs for the same indication on was also limited.

Colchicine (Myinfla™) Continued...

Other	None
Information	

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the <u>Drug Benefit Council (DBC)</u> gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the Common Drug Review (CDR)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit <u>The Drug Review Process in B.C. - Overview</u> and <u>Ministry of Health - PharmaCare</u> for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.